Late Phase Market Overview and Outlook (2013)

Report Overview

Late Phase studies are becoming more important to biopharmaceutical sponsors. As the line between clinical development and commercialization continues to blur, better decisions need to be made. In order to make better decisions, one needs better information. This report provides an analysis of current Late Phase clinical trial trends and outsourcing.

What you will learn:

• 3-year examination of the industry’s Phase IV study characteristics (i.e. study type, size, length)
• Average per company spend on Late Phase studies
• Study conduct and outsourcing penetration across 16 Late Phase study types
• Sponsors’ organizational hierarchy for Late Phase decision-making
• Criteria sponsors use to select (and disqualify) clinical service providers by study type

How you can use this report:

For Sponsors: Benchmark Late Phase study design and conduct against industry-wide, study specific trends to make more informed operational, resourcing, and outsourcing decisions.

For Service Providers: Drive operational and Late Phase sales strategies by understanding what studies are being conducted, which services sponsors are buying, what they will be buying, how they buy, where they will buy, and how they select clinical service providers

Report Contents:

1. Growth and Decline in Study Conduct and Outsourcing
2. A 3-year History of Phase IV Studies
3. Service Provider Dynamics
4. Decision-making for Late Phase Studies
5. Study Data